Findings

What do systematic reviews say?

4,736 questions · 15,265 findings · 1,163 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,871 · 25.4%GRADE not reported 810 · 5.3%Very low 4,242 · 27.8%Low 3,879 · 25.4%Moderate 1,999 · 13.1%High 464 · 3%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Intracameral mydriatics vs depot delivery systems

Mean pupillary diameter—at the time the surgeon performs capsulorhexis (mm) · patients undergoing cataract surgery

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical mydriatics vs intracameral mydriatics

Mean pupillary diameter—at the beginning of cataract surgery (mm) · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 242 participants
Low

Intracameral mydriatics vs depot delivery systems

Mean pupillary diameter—at the beginning of cataract surgery (mm) · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Intracameral mydriatics vs depot delivery systems

Mean pupillary diameter—at the end of cataract surgery (mm) · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Intracameral mydriatics vs depot delivery systems

Intraoperative surgical time—total intraoperative time (min) · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Intracameral mydriatics vs depot delivery systems

AE: participant‐reported ocular discomfort—week 1 · patients undergoing cataract surgery

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intracameral mydriatics vs depot delivery systems

AE: participant‐reported ocular discomfort—month 1 · patients undergoing cataract surgery

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intracameral mydriatics vs depot delivery systems

Adverse events · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Topical mydriatics vs intracameral mydriatics

Mean pupillary diameter—at the end of cataract surgery (mm) · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 799 participants
Low

Topical mydriatics vs intracameral mydriatics

Intraoperative surgical time—total intraoperative time (min) · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 817 participants
Low

Topical mydriatics vs intracameral mydriatics

Total time it took for the surgeon to perform phacoemulsification (seconds) · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 48 participants
Very low

Topical mydriatics vs intracameral mydriatics

AE: participant‐reported ocular discomfort—week 1 · patients undergoing cataract surgery

It is very uncertain whether topical mydriatics changes AE: participant‐reported ocular discomfort—week 1 compared with intracameral mydriatics (very low certainty).

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
RR 10.57 [1.37, 81.34]
1 study · 555 participants
Very low

Topical mydriatics vs intracameral mydriatics

AE: participant‐reported ocular discomfort—month 1 · patients undergoing cataract surgery

Topical mydriatics probably leads to higher AE: participant‐reported ocular discomfort—month 1 compared with intracameral mydriatics (moderate certainty).

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
RR 2.51 [1.36, 4.65]
1 study · 543 participants
Moderate

Topical mydriatics vs intracameral mydriatics

AE: posterior capsule rupture · patients undergoing cataract surgery

Topical mydriatics showed no clear difference in AE: posterior capsule rupture compared with intracameral mydriatics (low certainty).

2 findings from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
RR 0.32 [0.01, 7.83]
1 study · 555 participants
Low
Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
RR 0.32 [0.01, 7.83]
1 study · 555 participants
Low

Eculizumab vs placebo or alternative treatment

Death · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Ravulizumab vs placebo or alternative treatment

Remission · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
56 participants
Very low

Ravulizumab vs placebo or alternative treatment

Change in eGFR · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
56 participants
Very low

Ravulizumab vs placebo or alternative treatment

Health‐related quality of life · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
44 participants
Very low

Ravulizumab vs placebo or alternative treatment

Adverse events · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
58 participants
Very low

Ravulizumab vs placebo or alternative treatment

Meningococcal infection · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
58 participants
Very low